WallStreetZenWallStreetZen

NASDAQ: RLAY
Relay Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for RLAY

Based on 7 analysts offering 12 month price targets for Relay Therapeutics Inc

Min Forecast
$14.00-13.1%
Avg Forecast
$18.29+13.51%
Max Forecast
$22.00+36.56%

Should I buy or sell RLAY stock?

Based on 7 analysts offering ratings for Relay Therapeutics Inc.

Strong Buy
Strong Buy
3 analysts 42.86%
Buy
3 analysts 42.86%
Hold
1 analysts 14.29%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although RLAY's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates RLAY as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their RLAY stock forecasts and price targets.

RLAY stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-04-14
lockedlocked$00.00+00.00%2026-04-08Find Out Why
lockedlocked$00.00+00.00%2026-03-23
lockedlocked$00.00+00.00%2026-03-17
lockedlocked$00.00+00.00%2026-03-17
Guggenheim
Top 17%
84
Strong BuyMaintains$22.00+36.56%2026-03-13Find out why
Oppenheimer
Bottom 8%
8
BuyUpgrades$14.00-13.10%2026-01-26

1 of 1

Forecast return on equity

Is RLAY forecast to generate an efficient return?

Company
-21.54%
Industry
67.94%
Market
159.1%
RLAY's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is RLAY forecast to generate an efficient return on assets?

Company
-19.66%
Industry
31.34%
RLAY is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

RLAY earnings per share forecast

What is RLAY's earnings per share in the next 3 years based on estimates from 13 analysts?

Avg 1 year Forecast
-$1.56
Avg 2 year Forecast
-$1.54
Avg 3 year Forecast
-$1.57

RLAY revenue forecast

What is RLAY's revenue in the next 3 years based on estimates from 12 analysts?

Avg 1 year Forecast
$4.1M-73.28%
Avg 2 year Forecast
$17.4M+13.31%
Avg 3 year Forecast
$20.0M+30.11%
RLAY's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

RLAY revenue growth forecast

How is RLAY forecast to perform vs Biotechnology companies and vs the US market?

Company
13.04%
Industry
38.23%
Market
14.39%
RLAY's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
RLAY's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

RLAY vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
RLAY$16.11$18.29+13.51%Strong Buy
TARS$67.72$96.60+42.65%Strong Buy
IDYA$32.51$55.46+70.58%Strong Buy
RCUS$23.59$31.11+31.88%Buy
MANE$74.12$78.33+5.68%Strong Buy
View Top Biotech Stocks

Relay Therapeutics Stock Forecast FAQ

Is Relay Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 7 Wall Street analysts covering (NASDAQ: RLAY) stock is to Strong Buy RLAY stock.

Out of 7 analysts, 3 (42.86%) are recommending RLAY as a Strong Buy, 3 (42.86%) are recommending RLAY as a Buy, 1 (14.29%) are recommending RLAY as a Hold, 0 (0%) are recommending RLAY as a Sell, and 0 (0%) are recommending RLAY as a Strong Sell.

If you're new to stock investing, here's how to buy Relay Therapeutics stock.

What is RLAY's earnings growth forecast for 2026-2028?

(NASDAQ: RLAY) Relay Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.58%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 35.95%.

Relay Therapeutics's earnings in 2026 is -$276,479,000.On average, 13 Wall Street analysts forecast RLAY's earnings for 2026 to be -$279,419,930, with the lowest RLAY earnings forecast at -$343,296,534, and the highest RLAY earnings forecast at -$234,577,624. On average, 10 Wall Street analysts forecast RLAY's earnings for 2027 to be -$275,041,147, with the lowest RLAY earnings forecast at -$376,575,280, and the highest RLAY earnings forecast at -$225,194,519.

In 2028, RLAY is forecast to generate -$280,438,667 in earnings, with the lowest earnings forecast at -$397,593,435 and the highest earnings forecast at -$202,675,067.

What is RLAY's revenue growth forecast for 2026-2028?

(NASDAQ: RLAY) Relay Therapeutics's forecast annual revenue growth rate of 13.04% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.23%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.39%.

Relay Therapeutics's revenue in 2026 is $15,355,000.On average, 12 Wall Street analysts forecast RLAY's revenue for 2026 to be $733,311,994, with the lowest RLAY revenue forecast at $0, and the highest RLAY revenue forecast at $2,814,931,492. On average, 10 Wall Street analysts forecast RLAY's revenue for 2027 to be $3,109,471,625, with the lowest RLAY revenue forecast at $0, and the highest RLAY revenue forecast at $13,399,252,627.

In 2028, RLAY is forecast to generate $3,570,762,938 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $10,419,535,939.

What is RLAY's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: RLAY) forecast ROA is -19.66%, which is lower than the forecast US Biotechnology industry average of 31.34%.

What is RLAY's Price Target?

According to 7 Wall Street analysts that have issued a 1 year RLAY price target, the average RLAY price target is $18.29, with the highest RLAY stock price forecast at $22.00 and the lowest RLAY stock price forecast at $14.00.

On average, Wall Street analysts predict that Relay Therapeutics's share price could reach $18.29 by Apr 14, 2027. The average Relay Therapeutics stock price prediction forecasts a potential upside of 13.51% from the current RLAY share price of $16.11.

What is RLAY's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: RLAY) Relay Therapeutics's current Earnings Per Share (EPS) is -$1.61. On average, analysts forecast that RLAY's EPS will be -$1.56 for 2026, with the lowest EPS forecast at -$1.92, and the highest EPS forecast at -$1.31. On average, analysts forecast that RLAY's EPS will be -$1.54 for 2027, with the lowest EPS forecast at -$2.11, and the highest EPS forecast at -$1.26. In 2028, RLAY's EPS is forecast to hit -$1.57 (min: -$2.22, max: -$1.13).

What is RLAY's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: RLAY) forecast ROE is -21.54%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.